Katagiri, YukiOnuma, YoshinobuAsano, TakuIñiguez Romo, AndresJensen, Lisette OkkelsCequier Fillat, Àngel R.Hofma, Sjoerd H.Christiansen, Evald H.Suttorp, MaartenBrugaletta, SalvatoreRäber, LorenzSabaté Tenas, ManuelWindecker, StephanSerruys, Patrick W.2020-11-232018-12-071774-024Xhttps://hdl.handle.net/2445/172268Previous midterm follow-up reports after implantation of the Absorb everolimus-eluting bioresorbable scaffold (BRS; Abbott Vascular, Santa Clara, CA, USA) in stable coronary artery disease and acute coronary syndrome have shown an increase of scaffold thrombosis leading to an excess of the device-oriented composite endpoint (DOCE: a composite of cardiac death, target vessel myocardial infarction [TVMI], and clinically driven target lesion revascularisation [CD-TLR])1. In contrast, in the six-month primary report of ABSORB STEMI: the TROFI II Study (NCT01986803)2, which randomised patients with ST-elevation myocardial infarction (STEMI) to receive either the Absorb BRS or the XIENCE metallic everolimus-eluting stent (EES; Abbott Vascular), optical frequency domain imaging (OFDI)-derived healing score was comparable between the BRS arm and the EES arm. The aim of this report was to present the three-year clinical outcome results of the BRS and the metallic EES at the time when full resorption of the scaffold device can be expected.1 p.application/pdfeng(c) EuroPCR and the European Association of Percutaneous Cardiovascular Interventions, 2018Malalties coronàriesInfart de miocardiCoronary diseasesMyocardial infarctioninfo:eu-repo/semantics/article6846142020-11-23info:eu-repo/semantics/embargoedAccess30398967